FDA Asks Endo Pharma to Take Opana ER Off the Market FDA Asks Endo Pharma to Take Opana ER Off the Market
For the first time, the FDA has asked a company to remove a currently marketed opioid pain medication from the market because of the public health consequences of abuse.News Alerts
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news
More News: Brain | Health | International Medicine & Public Health | Neurology | Neurosurgery | Opana | Pain | Pharmaceuticals